Globus Medical jumps as raised 2026 EPS outlook fuels renewed buying interest
Globus Medical shares rose about 3% as investors rotated into med-tech names and revisited the company’s raised 2026 profit outlook following strong 2025 results. The next major catalyst is the May 12, 2026 earnings report, keeping attention on margin expansion and Nevro integration progress.
1) What’s moving GMED today
Globus Medical (GMED) traded higher Friday as the market continued to reward med-tech companies showing improving profitability, with traders leaning on the company’s most recently updated 2026 outlook. In late February, Globus reaffirmed 2026 revenue guidance of $3.18–$3.22 billion while lifting non-GAAP diluted EPS guidance to $4.40–$4.50, a combination that has helped support the stock on pullbacks and can spark incremental buying when risk appetite improves. (globenewswire.com)
2) The fundamental backdrop investors are keying on
The recent results narrative has centered on operating leverage and integration benefits, including contributions from the Nevro acquisition, alongside expectations for gross margin expansion. That earnings and guidance reset remains the clearest, widely circulated fundamental driver in the current information set, and it has helped anchor bullish price targets across Wall Street coverage. (globenewswire.com)
3) What comes next
The next scheduled catalyst is the company’s upcoming quarterly report, currently flagged for May 12, 2026. Into that date, investors will be focused on whether Globus can sustain margin momentum and execution against the 2026 EPS range while keeping growth on track. (investing.com)